ARMP stock icon

Armata Pharmaceuticals


About: Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Employees: 75

Funds holding %
of 6,689 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

42% more capital invested

Capital invested by funds: $4.17M [Q4 2023] → $5.93M (+$1.76M) [Q1 2024]

0.36% more ownership

Funds ownership: 3.57% [Q4 2023] → 3.93% (+0.36%) [Q1 2024]

4% less funds holding

Funds holding: 25 [Q4 2023] → 24 (-1) [Q1 2024]

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Research analyst outlook

We haven’t received any recent analyst ratings for ARMP.

Financial journalist opinion